---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-26-000025"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:37:45.616820+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics 2025 net loss $11.6M; cash $11.9M; TNBC trial pCR 71% vs 33%

## Summary
- Net loss narrowed to $11.6M from $16.3M in 2024; R&D spend fell to $6.8M from $10.5M.
- Cash and equivalents $11.9M at Dec 31, 2025; raised >$20M in 2025; runway into Q2 2027.
- INVINCIBLE-4 TNBC trial: 5/7 (71.4%) pCR with INT230-6+SOC vs 2/6 (33%) SOC alone; fewer grade 3+ AEs.
- INVINCIBLE-3 sarcoma trial paused in March 2025; 21 patients enrolled; restart depends on funding.
- IT-01 study published in eBioMedicine: 75% disease control rate, median OS 11.9 months in refractory tumors.

## SEC filing metadata
- accession: 0001567264-26-000025
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000025/0001567264-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000025/intensity-20260327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-26-000025
- JSON: https://secwatch.observer/filing/0001567264-26-000025.json
- Plain text: https://secwatch.observer/filing/0001567264-26-000025.txt

## Key facts
- Earnings Releases
  INTENSITY THERAPEUTICS, INC. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: On March 27, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000025/0001567264-26-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.